9

STERO’s IP:

STERO has filed a patent on May 2017, the patent was granted on August 2018.
The first clinical trial will commence on Q4 2018 in the first indication with other indications in the pipeline to be researched on 2019.

The patent named CANNABIDIOL FOR REDUCING A STEROID DOSE AND TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES was approved in a little over a year!.

Patent coverage:

The patent covers the use of CBD for enhancing the therapeutic effect of a steroid, reducing the dose of steroid treatment and for reducing side effects associated with steroids.

Over 100 diseases are covered by the patent, Including Chronic inflammatory diseases and more than 70 Auto-Immune diseases.
More importantly, patients with immune diseases that cannot otherwise benefit from CBD treatments (drug not developed for the specific indication as to no patent protection) – can benefit from our treatment and reduce the dose of steroids used to treat their disease.